Rosette Lidereau

Rosette Lidereau's AcademicInfluence.com Rankings

Rosette Lidereau

Biology

#11918

World Rank

#15352

Historical Rank

Immunology

#783

World Rank

#806

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Rosette Lidereau Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rosette Lidereau's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (2007) (2668)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors (2009) (1606)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. (2006) (1199)
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007) (983)
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. (2006) (531)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy (2007) (525)
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (2011) (459)
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. (1986) (440)
Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. (2003) (356)
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. (1998) (353)
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues (2007) (328)
Genetic alterations in breast cancer (1995) (315)
Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia (1987) (285)
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. (1999) (274)
Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. (1999) (268)
Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. (1995) (266)
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers (2011) (263)
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. (2001) (263)
A refined molecular taxonomy of breast cancer (2011) (257)
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites (1998) (251)
Molecular Profiling of Inflammatory Breast Cancer (2004) (239)
Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. (1994) (238)
Novel approach to quantitative polymerase chain reaction using real‐time detection: Application to the detection of gene amplification in breast cancer (1998) (235)
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants (2012) (232)
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. (1986) (230)
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. (2006) (220)
Prognostic value of ERBB family mRNA expression in breast carcinomas (2003) (216)
VEGF overexpression in clinically localized prostate tumors and neuropilin‐1 overexpression in metastatic forms (2000) (197)
Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. (2000) (193)
NF-kappa B genes have a major role in Inflammatory Breast Cancer (2008) (186)
Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer (1992) (183)
Amplification of the int-2 gene in primary human breast tumors. (1988) (178)
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups (2012) (175)
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. (2007) (174)
Somatic allelic deletion of nm23 in human cancer. (1991) (173)
Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. (2003) (171)
microRNA expression profile in a large series of bladder tumors: Identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancer (2013) (165)
CXC chemokines located in the 4q21 region are up-regulated in breast cancer. (2007) (164)
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. (2009) (163)
Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. (1997) (153)
PTEN/MMAC1/TEP1 involvement in primary prostate cancers (1998) (149)
Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis (2007) (147)
A six-gene signature predicting breast cancer lung metastasis. (2008) (145)
Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: two additional regions identified. (1990) (143)
Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours (1999) (139)
Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. (1995) (134)
(C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. (1994) (133)
Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. (2001) (130)
The amplification unit on chromosome 11q13 in aggressive primary human breast tumors entails the bcl-1, int-2 and hst loci. (1989) (129)
Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based Approach Versus Molecular Screening (2008) (128)
Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene (2008) (122)
Quantification of estrogen receptor α and β expression in sporadic breast cancer (2001) (122)
Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. (1996) (119)
Two distinct regions involved in 1p deletion in human primary breast cancer. (1993) (118)
Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells (2006) (114)
Significant Contribution of Germline BRCA2 Rearrangements in Male Breast Cancer Families (2004) (113)
ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. (1986) (112)
Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness (2012) (111)
Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors (2002) (111)
Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. (1988) (109)
Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma (2004) (107)
Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. (1989) (106)
Somatic mutations and human breast cancer. A Status Report (1992) (102)
Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. (1989) (101)
htert expression correlates with MYC over‐expression in human prostate cancer (2000) (101)
In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast. (1988) (97)
Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays (2002) (97)
Overexpression of the stathmin gene in a subset of human breast cancer. (1998) (96)
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. (2000) (96)
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk (2012) (94)
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases (2011) (94)
High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. (1986) (94)
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. (2000) (93)
Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. (1996) (92)
Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells (2007) (91)
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. (1998) (89)
Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. (1997) (88)
Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q (1994) (87)
Genetic pathways in the evolution of breast ductal carcinoma in situ (2002) (86)
PIK3R1 underexpression is an independent prognostic marker in breast cancer (2013) (85)
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. (1996) (84)
Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. (1993) (84)
Expression of ANRIL–Polycomb Complexes–CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value (2016) (84)
Inhibition of the Wnt/β-catenin pathway by the WWOX tumor suppressor protein (2009) (83)
Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. (2006) (83)
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer (2002) (83)
Overexpression of BRCA2 gene in sporadic breast tumours (1999) (81)
Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas. (1994) (77)
Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. (1987) (76)
Loss of heterozygosity on chromosome arm 16q in breast cancer metastases (1997) (75)
Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. (2010) (75)
Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. (2001) (75)
miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness (2013) (73)
Update on inflammatory breast cancer (2005) (72)
Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. (2010) (72)
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. (2001) (70)
Quantitative PCR high‐resolution melting (qPCR‐HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: application to MLH1 germline mutations in Lynch syndrome (2009) (70)
Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. (2011) (69)
Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer (2016) (68)
Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. (1995) (68)
High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. (2007) (67)
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. (2008) (66)
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy (2011) (64)
Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. (2001) (62)
Loss and gain of distinct regions of chromosome 1q in primary breast cancer. (1995) (62)
Chromosome region 8p11‐p21: Refined mapping and molecular alterations in breast cancer (1998) (62)
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene‐expression levels (2008) (61)
Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. (2003) (61)
The contribution of germline rearrangements to the spectrum of BRCA2 mutations (2006) (61)
Deletion mapping of chromosomal region 1p32‐pter in primary breast cancer (1999) (61)
Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52 (2008) (60)
Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study (2005) (59)
Novel indications for BRCA1 screening using individual clinical and morphological features (1999) (58)
Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway (2010) (57)
Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. (2005) (56)
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (55)
MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers? (2015) (53)
Hedgehog pathway activation in human transitional cell carcinoma of the bladder (2012) (52)
Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. (2004) (51)
Real‐time PCR‐based gene dosage assay for detecting BRCA1 rearrangements in breast–ovarian cancer families (2004) (51)
A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. (1994) (51)
Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. (2001) (50)
Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumor breast tissue compared with normal tissue. (1999) (50)
Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. (1998) (49)
Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer (2006) (49)
NME1 protein expression and loss of heterozygosity mutations in primary human breast tumors. (1994) (48)
Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer (2000) (48)
Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO) (2011) (48)
Genetic aspects of prostate cancer (1998) (48)
Oncogene amplifications in early‐stage human prostate carcinomas (1994) (47)
High‐resolution oligonucleotide array‐CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1 (2007) (47)
Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases (2010) (47)
Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. (2009) (47)
Genetic alteration mapping on chromosome 7 in primary breast cancer. (1997) (47)
Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene (1999) (46)
Location of several putative genes possibly involved in human breast cancer progression. (1998) (45)
MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. (1997) (45)
Multiple sequence variants of BRCA2 exon 7 alter splicing regulation (2012) (45)
11q13 Amplification in local recurrence of human primary breast cancer (1995) (44)
Alteration of Met protooncogene product expression and prognosis in breast carcinomas. (1999) (44)
Molecular alterations in sporadic breast cancer. (2002) (43)
Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients. (1985) (43)
ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels (2015) (42)
Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. (2011) (42)
Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. (2006) (41)
Similar NF-κB Gene Signatures in TNF-α Treated Human Endothelial Cells and Breast Tumor Biopsies (2011) (40)
A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. (1997) (40)
Identification of a three-gene expression signature of poor-prognosis breast carcinoma (2004) (40)
mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients. (1989) (40)
Unclassified variants identified in BRCA1 exon 11: Consequences on splicing (2008) (39)
Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. (1995) (38)
Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. (2006) (38)
Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests (2013) (38)
Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. (1999) (38)
SIMULTANEOUS MEASUREMENT OF 23 ISOFORMS FROM THE HUMAN CYTOCHROME P450 FAMILIES 1 TO 3 BY QUANTITATIVE REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (2005) (36)
DNA repair gene expression and risk of locoregional relapse in breast cancer patients. (2010) (36)
Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. (2004) (35)
Somatic genetic alterations (loh) in benign, borderline and invasive ovarian tumours: Intratumoral molecular heterogeneity (1999) (35)
Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas (2002) (34)
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation (2011) (34)
Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. (2002) (33)
Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study (1999) (33)
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. (2008) (33)
Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis (2007) (33)
Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays. (2001) (33)
Allelic Loss Detection in Inflammatory Breast Cancer: Improvement with Laser Microdissection (2001) (33)
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO) (2012) (33)
Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP (2010) (32)
Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions (2011) (32)
Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer. (2001) (32)
Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer (1999) (31)
Prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas (2003) (31)
Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. (2007) (31)
Evaluation of mRNA expression of estrogen receptor β and its isoforms in human normal and neoplastic endometrium (2004) (30)
BRCA2 mutations in hereditary breast and ovarian cancer in France. (1997) (30)
TPD52 represents a survival factor in ERBB2‐amplified breast cancer cells (2014) (30)
Evidence of chromosome regions and gene involvement in inflammatory breast cancer (2002) (30)
Antitumoral activity of dipyrido [4,3-b] [3,4-f] indoles on L 1210 leukemia. (1980) (30)
Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis (1995) (30)
Variations in the mRNA expression of poly(ADP‐ribose) polymerases, poly(ADP‐ribose) glycohydrolase and ADP‐ribosylhydrolase 3 in breast tumors and impact on clinical outcome (2013) (29)
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene (2005) (28)
Quantification of PKC family genes in sporadic breast cancer by qRT‐PCR: Evidence that PKCι/λ overexpression is an independent prognostic factor (2012) (28)
Loss of heterozygosity at 7q31 in breast cancer: results from an International Collaborative Study Group. The Breast Cancer Somatic Genetics Consortium. (1997) (28)
Epidermal growth factor receptors and prognosis in primary breast cancer (1990) (28)
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast‐ovarian cancer family (2003) (27)
Identification of new candidate therapeutic target genes in triple-negative breast cancer. (2012) (27)
Gene Characterization, Promoter Analysis, and Chromosomal Localization of Human Bleomycin Hydrolase* (1997) (27)
Chapter 6 Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer (2009) (25)
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers (2009) (25)
Competitive prognostic value of clinicopathologic and bioimmunologic factors in primary breast cancer (1986) (25)
An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition (2011) (25)
Genome-based and transcriptome-based molecular classification of breast cancer (2011) (25)
Genetic and molecular heterogeneity of breast cancer cells. (1993) (25)
Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs (2012) (25)
Differential chromosome allelic imbalance in the progression of human prostate cancer. (1996) (24)
Sequences related to mouse mammary tumor virus genome in tumor cells and lymphocytes from patients with breast cancer. (1984) (24)
The CGA gene as new predictor of the response to endocrine therapy in ERα-positive postmenopausal breast cancer patients (2001) (23)
Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma. (2005) (22)
Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition (2012) (22)
Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk (2018) (21)
Molecular analysis of the FHIT gene in human prostate cancer (1998) (21)
Association between restriction fragment length polymorphism of the L‐myc gene and lung metastasis in human breast cancer (1992) (21)
A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2 (2012) (20)
Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: A candidate biomarker to predict EGFR inhibitor effectiveness (2012) (20)
Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. (1994) (20)
Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers (1998) (20)
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene expression levels (2008) (20)
The growing family of hereditary renal cell carcinoma. (2004) (20)
Gene amplifications in advanced-stage human prostate cancer (2004) (20)
Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. (1990) (20)
A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis. (2010) (19)
Genetic variability of proto-oncogenes for breast cancer risk and prognosis. (1988) (19)
Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours (1997) (19)
Expression of Colony‐Stimulating Factor‐1 and Its Receptor (the Protein Product of c‐fms) in Invasive Breast Tumor Cells (1993) (19)
Definition of regions of the human genome affected by loss of heterozygosity in primary human breast tumors (1993) (18)
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA 1 / BRCA 2 databases (2011) (18)
[Genetics and breast cancer]. (1990) (18)
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. (2005) (18)
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables (1999) (18)
BRCA 1 R 1699 Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk (2012) (18)
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. (2003) (18)
Enhancement of retrovirus production by anti-interferon serum. (1979) (18)
Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes (2016) (17)
Distinct expression profiles and functions of Kindlins in breast cancer (2018) (17)
Heterogeneity of genetic alterations in primary human breast tumors. (1988) (17)
A missense variant within BRCA1 exon 23 causing exon skipping. (2010) (17)
VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX (2018) (16)
Deletion mapping in breast tumor cell lines points to two distinct tumor-suppressor genes in the 1p32-pter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma. (1998) (16)
Absence of p53 germ-line mutations in bilateral breast cancer patients (1992) (16)
A Methodological Approach to Unravel Organ-Specific Breast Cancer Metastasis (2012) (16)
Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma. (1997) (16)
Functional pathways shared by liver and lung metastases: a mitochondrial chaperone machine is up-regulated in soft-tissue breast cancer metastasis (2007) (16)
Relevance of multiple biological parameters in breast cancer prognosis (1996) (16)
CCND1 mRNA Overexpression is Highly Related to Estrogen Receptor Positivity but not to Proliferative Markers in Primary Breast Cancer (2000) (16)
CGA gene (Coding for the α subunit of glycoprotein hormones) overexpression in ERα-positive prostate tumors (2002) (15)
First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome (2011) (15)
Loss of heterozygosity of the L-myc oncogene in human breast tumors (1990) (15)
Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas (2016) (15)
Histological type and syncytial growth pattern affect E‐cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1‐associated breast cancers (1999) (15)
Involvement of the FOXO6 transcriptional factor in breast carcinogenesis (2017) (14)
Two prognostic groups of inflammatory breast cancer have distinct genotypes. (2003) (14)
Detection of telomerase status by semiquantitative and in situ assays, and by real‐time reverse transcription‐polymerase chain reaction (telomerase reverse transcriptase) assay in bladder carcinomas (2003) (14)
The BRCA2 gene is not relevant to sporadic prostate tumours (1996) (14)
Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR. (2005) (13)
Study of FHIT transcripts in normal and malignant breast tissue (1998) (13)
A mesofluidic multiplex immunosensor for detection of circulating cytokeratin-positive cells in the blood of breast cancer patients (2011) (13)
KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition (2008) (13)
Infrequent mutations of the MET gene in sporadic breast tumours (1999) (13)
Loss of heterozygosity, chromosome 7q, and breast cancer (1992) (12)
The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells (2015) (12)
Prediction of BRCA1 Germ-Line Mutation Status in Patients with Breast Cancer Using Histoprognosis Grade, MS110, Lys27H3, Vimentin, and KI67 (2013) (12)
CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER alpha-positive prostate tumors. (2002) (11)
ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma. (2001) (11)
Assessing the risk of BRCA1‐associated breast cancer using individual morphological criteria (2001) (11)
Breast cancer and T-cell-mediated immunity to proteins of the mouse mammary tumour virus (MMTV). (1993) (10)
Isolation of mineralizing Nestin+ Nkx6.1+ vascular muscular cells from the adult human spinal cord (2011) (10)
Classical gene amplifications in human breast cancer are not associated with distant solid metastases. (1997) (9)
A single point mutation responsible for c-mos polymorphism in cancer patients. (1987) (9)
Frequent Mutations in Breast Cancer (1993) (9)
Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. (2021) (9)
[A new model of human prostate cancer, the PAC120 xenograft]. (2003) (8)
Gene Expression Profiling Reveals New Aspects of PIK 3 CA Mutation in ERalpha-Positive Breast Cancer : Major Implication of the Wnt Signaling Pathway (2010) (8)
ABCC 11 expression is regulated by estrogen in MCF 7 cells , correlated with estrogen receptor a expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells (2008) (8)
The genetic pathology of breast cancer. (1992) (8)
Allelic loss at chromosome 8p in human breast-cancer. (1994) (8)
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study (2021) (7)
Brief communications oncogene amplification per se: An independent prognostic factor in human breast cancer (1994) (7)
TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer (2006) (7)
Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder? (2006) (7)
A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas (2013) (7)
Confounding effects in "a six-gene signature predicting breast cancer lung metastasis": reply. (2009) (6)
Identification of TACC 1 , NOV , and PTTG 1 as new candidate genes associated with endocrine therapy resistance in breast cancer (2009) (6)
Loss of a c-Hras-1 AlÃ-eleand Aggressive Human Primary Breast Carcinomas 1 (2006) (5)
Common Δ2 and Δ8 RB1 variants in human breast and prostate tissues (1999) (5)
5′ Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints (2021) (5)
Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR. (2005) (5)
[Demonstration of two regions involved in chromosome 1p deletion in breast tumors]. (1994) (5)
Loss of Heterozygosity at Chromosome 16 q in Prostate Adenocarcinoma : Identification of Three Independent Regions 1 (1997) (4)
Molecular Functions of WWOX Potentially Involved in Cancer Development (2021) (4)
Differential chromosome allelic imbalance in the progression of human prostate cancer (1996) (4)
[Oncogenes: risk and prognostic factors in cancer of the breast]. (1988) (4)
Common BRCA 2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA 1 Mutation Carriers (2005) (4)
MicroRNA Expression Profiling of Inflammatory Breast Cancer. (2009) (4)
Somatic genetic alterations in breast cancer (1997) (4)
Oncogene amplification per se: an independent prognostic factor in human breast cancer. (1994) (4)
Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results (2005) (3)
Common delta2 and delta8 RB1 variants in human breast and prostate tissues. (1999) (3)
[Somatic genetics of breast cancer]. (1997) (3)
Erratum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (Nature (2011) 480:94-98 doi:10.1038/nature10539) (2016) (3)
Fluorescence In Situ Hybridization and Immunohistochemical Assays for HER-2/neu Status Determination (2009) (3)
The TLR4 polymorphism predicts the response of breast cancer patients to anthracyclins (2007) (3)
Leukocyte migration inhibition by Mu-MTV-enriched extracts in breast cancer patients (1983) (3)
The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis (2020) (3)
An EcoRI restriction fragment length polymorphism (RFLP) in the human c-erb A locus (2004) (2)
Therapy Candidate Marker to Predict the Response to Endocrine Receptor-responsive Gene in Breast Cancer : An Outstanding as a Novel Estrogen CGA Identification of Updated (2001) (2)
[Expression of MMTV proviruses in lymphopoietic organs of C3H Bi mice]. (1985) (2)
Human MutationMETHODS Quantitative PCR High-Resolution Melting ( qPCR-HRM ) Curve Analysis , a New Approach to Simultaneously Screen Point Mutations and Large Rearrangements : Application to MLH 1 Germline Mutations in Lynch Syndrome (2009) (2)
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (2015) (2)
[Genetic alterations in localized cancers of the prostate: identification of a common region of deletion on the chromosome 18q]. (1995) (2)
Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors. (1995) (2)
[A new marker of aggressivity of breast cancers: loss of heterozygote on chromosome 7q]. (1992) (2)
975 Genetic alterations in breast cancer (1995) (2)
452 Loss of heterozygosity on 7Q31 occurs early during breast tumorigenesis (1995) (2)
[Molecular analysis of breast cancers: recent developments]. (1992) (2)
TaqI RFLP of the TGFα gene in breast cancer (1990) (2)
Common genetic pathways in breast oncogenesis. (1992) (2)
169 MicroRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature predictive of aggressiveness and prognosis of muscle-invasive bladder cancer (2012) (2)
Molecular characterization of the genetic risk in breast cancer. (1989) (2)
BRCA 1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA 1 GermLine Mutations 1 (2003) (2)
Advances in Brief Identification of Three Regions on Chromosome 17 q in Primary Human Breast Carcinomas Which Are Frequently Deleted I (2007) (2)
Tissue glycolytic enzymes in primary breast cancer patients receiving adjuvant chemotherapy. (1986) (2)
Abstract 4303: Vopp1 physically interacts with Wwox and inhibits its apoptotic function in breast cancer (2017) (1)
[Cancer of the breast. Genetic alterations and prognostic factors]. (1990) (1)
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I (2021) (1)
Advances in Brief Increased Level of Exon 12 Alternatively Spliced BRCA 2 Transcripts in Tumor Breast Tissue Compared with Normal Tissue 1 (2000) (1)
TaqI RFLP of the TGF alpha gene in breast cancer. (1990) (1)
PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups (2012) (1)
451b Int-2/FGF3 amplification is a better independent predictor of relapse than C-MYC and c-erbB-2/neu amplifications in primary human breast cancer (1995) (1)
Transcriptome analysis reveals an osteomimetic phenotype for human bone metastatic breast cancer cells (2006) (1)
[Association studies in cancerology: the example of gene L-myc polymorphism associated with the incidence of pulmonary metastases in breast cancers]. (1992) (1)
Close proximity of c-erbA2 and c-erbA-beta genes on the short arm of chromosome 3. (1993) (1)
Prognostic Value of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) Content of Human Breast Carcinomas: Correlation with Clinical and Histologic Features and Hormone Receptors (1986) (1)
Trimodal GSTT1 and GSTM1 Genotyping Assay by Real-Time PCR (2005) (1)
Molecular analyses of human breast cancer metastasis: genetic markers of progression (2000) (1)
Referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: A nationwide study based on 240,134 consultations and 134,652 genetic tests. (2013) (1)
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1/2 carrier cohort (GENEPSO) (2018) (1)
Génétique et cancer: application au sein. (1995) (1)
A gene dosage effect is responsible for overexpression of the MUC1 gene in human breast cancer (1996) (1)
Review Update on inflammatory breast cancer (2005) (1)
P1-05-03: Relationship between Polycomb Repressive Complex EZH2/CBX7, Large Non-Coding RNA ANRIL and Stem Cells Biomarkers in Triple Negative Breast Carcinomas: Important Role in Carcinogenesis through an Epigenetic Silencing Process and New Clues for Targeted Therapies. (2011) (1)
[Biology of solid cancers: breast cancer as an example. First part: genetic systems implicated in carcinogenesis]. (1996) (1)
The current status of int genes, proto-oncogenes, and recessive mutations in primary human breast tumors: their potential usefulness in prognosis (1989) (1)
Gene profiling analysis of tissue-specific metastases from human breast cancer (2006) (1)
Prediction of BRCA 1 GermLine Mutation Status in Patients with Breast Cancer Using Histoprognosis Grade , MS 110 , Lys 27 H 3 , Vimentin , and KI 67 (2013) (1)
[Biology of solid cancers: breast cancer as an example. Second part: gene disregulation in breast cancer]. (1996) (0)
451a A tumor suppressor gene on chromosome 1P32-pter controls the amplification of MYC family genes in breast cancer (1995) (0)
Advances in Brief A Tumor Suppressor Gene on Chromosome Ip 32-pter Controls the Amplification of MYC Family Genes in Breast Cancer 1 (2006) (0)
Advances in Brief Two Distinct Regions Involved in Ip Deletion in Human Primary Breast Cancer 1 (2006) (0)
Abstract 3440: Genomic evolution of synchronous and metachronous breast cancer metastasis revealed from a prospective clinical trial (2018) (0)
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO) (2012) (0)
[Detection of telomerase activity by semi-quantitative and in situ assays and quantification of hTERT expression in bladder carcinomas]. (2003) (0)
799 Molecular subgroups of breast cancer show distinct genomic profiles and different clinical courses: a novel definition of disease subclasses (2010) (0)
DNA repair gene expression profile and risk of locoregional relapse in locally advanced breast cancer patients. (2009) (0)
MRNA EXPRESSION LEVELS AND PROGNOSTIC VALUE OF 40 ANGIOGENIC GENES IN A LARGE SERIES OF 157 BLADDER TUMOURS (2008) (0)
[Expression of CSF-1 (colony stimulating factor) and its receptor (c-fms) in breast tumors]. (1993) (0)
MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers? (2015) (0)
[Oncogenes and suppressor genes in breast cancer]. (1993) (0)
447 Classical gene amplifications in human breast cancer are not responsible of distant metastases (1995) (0)
PP-1-1 Refinement of the two regions on the long arm of chromosome 16 involved in breast cancer (1996) (0)
[Anti-ErbB targeted therapy and urothelial tumors]. (2005) (0)
Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients (2005) (0)
The Tumor-SuppressorWWOXandHDAC3 Inhibit the Transcriptional Activity of the b-Catenin Coactivator BCL9-2 in Breast Cancer Cells (2015) (0)
VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX (2018) (0)
HEDGEHOG PATHWAY INVOLVEMENT IN BLADDER CARCINOGENESIS: A STUDY OF 71 PATIENTS (2008) (0)
The immunohistochemical detection of CSF-1 (colony stimulating factor-1) in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates (1993) (0)
UN GENE SUPPRESSEUR DE METASTASE EST-IL LOCALISE SUR LE CHROMOSOME 7 ? (1992) (0)
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study (2021) (0)
Expression of Estrogen α and β Variants, Androgen, and Progesterone Receptors in Human Normal and Neoplastic Endometrium (2005) (0)
Effect Of Reproductive Factors And Body Mass Index On The Mutation Localization-Specific Risk Of Breast Cancer In The French National BRCA1/2 Carrier Cohort (GENEPSO) (2011) (0)
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers. (2023) (0)
Author's response to reviews Title: PIK3R1 underexpression is an independent prognostic marker in breast cancer Authors: (2013) (0)
Modification of the Regulation of Interleukin 2 (IL2) in Human Breast Cancer (1985) (0)
349 Glycolytic enzymes in human breast carcinoma cytosols: The influence of commonly used reference parameters on the results (1983) (0)
PIK3R1 underexpression is an independent prognostic marker in breast cancer (2013) (0)
Comparison between Glycolytic Enzyme Activities in Benign and Malignant Breast Tumors (1985) (0)
Glycolytic enzymes in human breast carcinoma cytosols: the influence of commonly used reference parameters. (1985) (0)
Up-regulation of a set of genes in breast cancer bone metastases discloses predisposition to generate metastases also in visceral organs (2011) (0)
775: Levels of Expression of the Four ERBB Genes and their Eleven Ligands Using Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) in a Large Series of Bladder Tumors (2005) (0)
Participation of host cells: resistance or collaboration (2004) (0)
Advances in Brief Quantitation of MYC Gene Expression in Sporadic Breast Tumors with a Real-Time Reverse Transcription-PCR Assay 1 (1999) (0)
Germline MET pathogenic variants in papillary renal cell carcinomas type I: specific phenotype in French population and novel germline pathogenic variant MET c.3389T>C, p.(Leu1130Ser) (2021) (0)
[Acquired genetic abnormalities in cancer of the breast]. (1990) (0)
96: miR-146a and miR-146b-5p regulate the expression of the BRCA1 gene (2010) (0)
The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis (2020) (0)
The Tumor-SuppressorWWOXandHDAC 3 Inhibit the Transcriptional Activity of the b-Catenin Coactivator BCL 9-2 in Breast Cancer Cells (2015) (0)
Impact of STI571 (Imatinib) on the Pharmacokinetics and In Vivo Efficacy of Etoposide and/or Ifosfamide. (2006) (0)
Chain Reaction Assays by Real-Time Quantitative Reverse Transcription-Polymerase Progesterone Receptor Expression in Human Prostate Cancer ) , and β ER and α ER Evaluation of Androgen , Estrogen ( Updated (2001) (0)
A new genomic approach to describe the natural history of node negative breast cancer patients. (2006) (0)
773: Loss of Expression of Candidate Tumor Suppressor Gene ATIP/MTUS1 in Human Transitional Cell Carcinoma of the Bladder (2007) (0)
Kindlin‐1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types (2022) (0)
Distinct expression profiles and functions of Kindlins in breast cancer (2018) (0)
Front & Back Matter (2013) (0)
Kindlin‐1 drives early steps of breast cancer metastasis (2022) (0)
Evidence of the presence of both oncogene and tumor suppressor gene on chromosome 1q in primary breast cancer, together with a genic dosage effect (1994) (0)
SY-1-3 Loss of heterozygosity and prognosis (1996) (0)
MRNA EXPRESSION LEVELS AND PROGNOSTIC VALUE OF 40 ANGIOGENIC GENES IN A LARGE SERIES OF 157 BLADDER TUMORS (2008) (0)
Histone deacetylase HDAC7 as a key regulator of the angiogenic process (2006) (0)
Detection of telomerase status by semi quantitative and in situ assay (TRAP) and real-time RT-PCR hTERT assay in bladder carcinomas (2003) (0)
Variation of Breast Cancer Risk in the French National BRCA1/2 Carrier Cohort (GENEPSO) (2009) (0)
Delineation of molecular subgroups of breast cancer with distinct genomic profiles and different clinical courses: a novel definition of disease subclasses (2010) (0)
Molecular markers of invasiveness and metastasis (2004) (0)
[Loss of heterozygosis on the short arm of chromosome 3. Question of the encoding gene for thyroid hormone receptor]. (1991) (0)
INTERLEUKIN 2 (IL2) PRODUCTION BY LYMPHOCYTES OF HUMAN BREAST CANCER PATIENTS (1986) (0)
Animal Model Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach (2001) (0)
115 A Diagnostic Genetic Test for the Physical Mapping of Germline Rearrangements in the Susceptibility Breast Cancer Genes BRCA1 and BRCA2 (2012) (0)
The Identification of Large Rearrangements Involving Intron 2 of the CDH1 Gene in BRCA1/2 Negative and Breast Cancer Susceptibility (2022) (0)
[Potential genetic markers for prognosis and therapeutic response]. (1996) (0)
P2-13-10: Detection, Visualization and High Resolution Physical Mapping of Large Rearrangements by Molecular Combing in the Hereditary Breast Cancer Genes BRCA1 and BRCA2. (2011) (0)
[Genetics and cancer: application to the breast]. (1995) (0)
Abstract 3182: Kindlin-1 expression is associated with EGFR/RAS/MAPK activation and response to MEK inhibitors in triple-negative breast cancer (2020) (0)
Candidate molecular markers associated with endocrine resistance in breast carcinoma (2008) (0)

This paper list is powered by the following services:

Rosette Lidereau's Academic­Influence.com Rankings

Why Is Rosette Lidereau Influential?

Rosette Lidereau's Published Works

Published Works

Rosette Lidereau's AcademicInfluence.com Rankings